53562-51-9

Basic information

• Product Name: 2-Methyl-3-thiophenecarboxylic acid methyl ester
• Synonyms: 2-Methyl-3-thiophenecarboxylic acid methyl ester;Methyl 2-methylthiophene-3-carboxylate;Methyl 2-Methyl-3-thiophenecarboxylate
• CAS NO: 53562-51-9
• Molecular Formula: C₇H₈O₂S
• Molecular Weight: 156.204
• Mol File: 53562-51-9.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 202.412 °C at 760 mmHg
• Flash Point: 76.216 °C
• Appearance: /
• Density: 1.174 g/cm³
• Vapor Pressure: 0.293mmHg at 25°C
• Refractive Index: 1.532
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: 2-Methyl-3-thiophenecarboxylic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Methyl-3-thiophenecarboxylic acid methyl ester(53562-51-9)
• EPA Substance Registry System: 2-Methyl-3-thiophenecarboxylic acid methyl ester(53562-51-9)

Safety Data

• RIDADR: 1993
• HazardClass: 3
• PackingGroup: Ⅲ
• Hazardous Substances Data: 53562-51-9(Hazardous Substances Data)

Usage

General Description

2-Methyl-3-thiophenecarboxylic acid methyl ester is a chemical compound with the molecular formula C8H8O2S. It is a methyl ester derivative of 2-methyl-3-thiophenecarboxylic acid, which is a sulfur-containing heterocyclic compound. This chemical is commonly used in organic synthesis as a building block for the preparation of various pharmaceuticals and agrochemicals. It is also used as an intermediate in the production of dyes, fragrances, and flavorings. 2-Methyl-3-thiophenecarboxylic acid methyl ester is a colorless to pale yellow liquid with a strong, fruity odor and is considered to be potentially harmful if ingested or inhaled. It should be handled and stored with proper safety precautions.

InChI:InChI=1/C7H8O2S/c1-5-6(3-4-10-5)7(8)9-2/h3-4H,1-2H3

Upstream product

• 1918-78-1 2-methylthiophene-3-carboxylic acid 
• 74-88-4 methyl iodide 
• 67-56-1 methanol 
• 88-13-1 3-Thiophene carboxylic acid 
• 40018-26-6 1,4-dithiane-2,5-diol 
• 1830-54-2 3-oxopentanedioic acid dimethyl ester 

Downstream Products

• 88048-78-6 methyl 2-(bromomethyl)thiophene-3-carboxylate 
• 148564-47-0 milfasartan 
• 172292-52-3 2-[4-Butyl-5-(2'-cyano-biphenyl-4-ylmethyl)-2-methyl-6-oxo-6H-pyrimidin-1-ylmethyl]-thiophene-3-carboxylic acid methyl ester 
• 148564-34-5 methyl 2-<<4-butyl-2-methyl-6-oxo-5-<<2'-<1-(triphenylmethyl)-1H-tetrazol-5-yl><1,1'-biphenyl>-4-yl>methyl>-1(6H)-pyrimidinyl>methyl>-3-thiophenecarboxylate 
• 1334598-73-0 C₁₃H₁₂O₄S₂ 
• 1334598-77-4 C₁₃H₁₁NO₃S 
• 1259396-11-6 methyl 5-bromo-2-methylthiophene-3-carboxylate 
• 1334598-41-2 C₁₅H₁₄O₃S 
• 1334598-50-3 C₁₄H₁₄O₄S₂ 
• 1334598-54-7 C₁₄H₁₃NO₃S 
• 1334598-01-4 C₂₀H₁₈N₂O₂S₂ 
• 1334598-04-7 C₂₁H₂₀N₂O₂S₂ 
• 1334598-15-0 C₁₉H₁₅N₃O₂S 
• 1334598-18-3 C₁₉H₁₈N₂O₃S₃ 

Relevant articles and documents

The synthesis of four isomeric bisthienothiepinones

The displacement reaction between sodium thiophene-3-thiolate and methyl 3-(bromomethyl)thiophene-2-carboxylate (5) gave the expected thioether 7a. Basic hydrolysis afforded the carboxylic acid 7b; conversion to the acid chloride, and treatment of the latter with stannic chloride then produced the bisthienothiepinone 1. Using analogous reactions the isomers 2-4 were also synthesized.

Discovery of a potent glucokinase activator with a favorable liver and pancreas distribution pattern for the treatment of type 2 diabetes mellitus

Glucokinase (GK) is an enzyme that plays an important role as a glucose sensor while maintaining whole body glucose homeostasis. Allosteric activators of GK (GKAs) have the potential to treat type 2 diabetes mellitus. To identify novel GKAs, a series of compounds based on a thiophenyl-pyrrolidine scaffold were designed and synthesized. In this series, compound 38 was found to inhibit glucose excursion in an oral glucose tolerance test (OGTT) in mice. Optimization of 38 using a zwitterion approach led to the identification of the novel GKA 59. GKA 59 exhibited potent blood glucose control in the OGTT test as well as a favorable safety profile. Owing to low pancreatic distribution, compound 59 primarily activates GK in the liver. This characteristic could overcome limitations of other GKAs, such as hypoglycemia, increased plasma triglycerides, and loss of efficacy.

NOVEL THIOPHENECARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF

The object of the present invention is to provide a compound having a glucokinase-activating effect. A pharmaceutical composition comprising a compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient: wherein X means a nitrogen atom or CR6, wherein R6 means a hydrogen atom or a halogen atom; R1 means a hydrogen atom, a C1-C6 alkyl group, a C1-C6 alkoxy group or a C1-C6 alkylthio group; R2 means a hydrogen atom or a fluorine atom; R3 means a hydrogen atom or a C1-C6 alkyl group; and one of R4 and R5 means a hydrogen atom or a C1-C6 alkyl group, and the other means a C1-C6 alkylenecarboxylic acid, a C1-C6 alkylsulfonyl group, a C1-C6 alkylcarbonyl group, or CONH2.